SUMMARY Cross-sectional age-and sex-specific plasma lipid distributions (means, medians and selected percentiles) are given for 48,431 white participants in visit 1 of the Lipid Research Clinics (LRC) Prevalence Study. This study consisted of two visits in which 10 LRCs screened participants selected from well-defined North American target populations that included a broad range of sociodemographic subgroups.
AN ASSOCIATION between serum cholesterol and coronary heart disease (CHD) is well established.1 It is based on a variety of evidence including: the cholesterol content and dynamics of the human atherosclerotic plaque; the production of atherosclerotic lesions in animals by regimens inducing hypercholesterolemia and the regression of these lesions during low-cholesterol regimens; the high prevalence of premature vascular disease in certain genetic hypercholesterolemias; the occurrence of hypercholesterolemia in subjects with clinically manifested atherosclerotic disease, especially in the younger age groups; and epidemiological studies of populations in a variety of settings. Of special importance is the observation, through prospective epidemiological studies, that total serum cholesterol concentration is an important predictor of CHD in North American adults. 2' 3 Although parallel studies have focused on serum triglyceride levels as an independent risk factor, the evidence has been contradictory and inconclusive.4' I The need to translate hyperlipidemia into hyperlipoproteinemia was advocated by Gofman6 in the early 1950s, and reemphasized by Frederickson, Levy, and Lees7 in 1967. These concepts led to the development of a system for classifying hyperlipo-Hyperlipoproteinemias are an important public health concern because they are frequently associated with CHD, especially in young persons. Many researchers have attempted to measure the prevalence and the extent of the relationship of hyperlipoproteinemias with CHD. However, few such studies have been population based or have involved sufficient numbers; therefore, a better understanding of the overall contribution of hyperlipoproteinemias to CHD is still needed. Moreover, an adequate interpretation of the significance of hyperlipoproteinemia requires a description of the distribution of lipids and lipoproteins within populations.
With these and related issues in mind, the National Heart and Lung Institute (NHLI) organized a Task Force in 1970 to develop a long-range plan to combat arteriosclerosis that would use existing knowledge and pinpoint research areas that require further study. The Task Force Panel on Hyperlipidemia and Premature Atherosclerosis was charged with recommending ways of preventing premature atherosclerosis through the diagnosis and treatment of hyperlipidemia. The panel reviewed research of the Molecular Disease Branch of the NHLI and elsewhere, which indicated that lipoprotein patterns could provide important information not provided by blood cholesterol and triglyceride levels alone. The identification of distinct lipid transport disorders, "hyperlipoproteinemias," which had formerly been grouped under the general heading of familial hyperlipidemia or hypercholesterolemia, offered a more systematic approach to the study and treatment of these conditions. Among the recommendations10 of the Task Force was the creation of the Lipid Research Clinics (LRC) Program 
Methods
The North American Prevalence Study consisted of a series of studies conducted according to a standardized protocol. Subjects were selected according to approved procedures from well-defined target populations. Each study provided an independent contribution to the epidemiologic data base; none was required to be statistically representative of the entire North American population. The selected populations were deliberately diverse, covering a broad range of geographic, socioeconomic, occupational, age, sex, and ethnic groups.
The sampling strategies used for the populations were grouped into broad categories as follows:
PLASMA LIPID DISTRIBUTIONS/LRC Program Epidemiology Committee Lipid Laboratory Quality Control A special emphasis on laboratory quality control was dictated by two features of the LRC Prevalence Study: the long period of time over which the tests were made and the fact that each clinic laboratory did the determinations for all samples collected by that clinic. Under these conditions, controlling both longterm drift or stability and interlaboratory variation were crucial. To accomplish this, identical systems of internal quality control and external surveillance were used in each laboratory."2-14 These included calibration of instruments with common solutions of cholesterol and triolein primary standards, and daily quality control assessment by the use of common serum pools of known cholesterol and triglyceride concentrations. The laboratories established control limits that were used to evaluate each day's analyses. Results obtained from "out-of-control" analyses were rejected, and those analyses were repeated. The cholesterol concentrations of the common serum pools were assigned by the Lipid Standardization Laboratory, by use of a reference Abell-Kendall method, and the triglyceride concentrations were assigned by use of a chromotropic acid colorimetric method. These samples were used to assess both within-run variability and overall precision.
Comparability of the AA-I and AA-If Systems
Because some of the Prevalence Study lipid determinations were done with the AA-I before the program's conversion to the AA-II system, the comparability of these two systems is an important issue for the Prevalence Study. On the average, for frozen serum pools the AA-I instruments tended to produce cholesterol values 2.1% higher than the manual AbellKendall target values. In contrast, the AA-II instruments tended to give values 1.3% lower than target values. However, all study determinations were done on fresh samples and the comparative data on fresh samples indicate differences even less than the values mentioned.
On quality control samples, the AA-II instruments showed excellent precision for cholesterol within runs, between runs and among instruments, as reported earlier. '5 For analyses from common pools, the total standard deviation was small in AA-II instruments (3-4 mg/dl), with most of the variability due not to differences among instruments, but to variations within a single run on a single machine." Although the AA-I instruments did not appear quite as precise as the AA-IIs, the total standard deviation was still quite small, and the variability among instruments was similar to the run-to-run variability within a single instrument.
The standard deviations and accuracy of triglyceride determinations were similar for the two types of instruments on the frozen pools. As was true for cholesterol, most of the variability did not arise from differences between instruments, but from variation from sample to sample within a single laboratory.'6 429 other studies and usefulness of our results to researchers and practitioners alike, the following white examinees were also excluded from these analyses: 1127 participants whose blood specimens were frozen before determination of plasma lipids; 4640 participants who fasted less than 12 hours; 338 pregnant women, and 57 women for whom information on exogenous sex hormone usage was missing or uncertain. Data editing resulted in the exclusion of three other records due to invalid information on sex, race or age.
Consequently, of the 54,557 white participants screened at visit 1, 6126 records were excluded from analyses because of one or a combination of the exclusion criteria. Plasma Triglyceride for White Males For fasting white males ( fig. 4 and table 11-4), the age-specific plasma triglyceride means rise from 56 mg/dl for ages 0-9 years to a high of 151 mg/dl for ages 40-54 years. For the older age groups, the mean values gradually decline to about 130 mg/dl. Because of the skewed triglyceride distributions, comparable median values are lower. The age-specific medians rise from 51 mg/dl for ages 0-9 years to 124 mg/dl for ages 45-54 years, then decrease to 105 mg/dl at age 80 years. The ninety-fifth percentile rises from approximately 100 mg/dl for ages 0-9 years to a value of 318 mg/dl for ages 45-49 years, and then declines somewhat irregularly to 255-267 mg/dl above age 65 years.
Plasma Triglyceride for White Females Not Taking Sex Hormones
The age-specific mean values ( fig. 5 and table rise slightly but consistently from 60-64 mg/dl for ages 0-9 years to levels of 125-135 mg/dl for ages 55 years and over. Age-specific medians generally parallel the mean values but at a lower level, with the maximum difference being 23 mg/dl for ages 80 years and older. After an initial decline from 112 mg/dl at ages 0-4 years to 105 mg/dl at ages 0-9 years, the ninety-fifth percentile gradually rises to a peak of 262 mg/dl for ages 55-59 years and then declines somewhat thereafter. Discussion The LRC data confirm the rise in cholesterol levels among males and females from the teenage years to middle age, a characteristic of findings in developed countries."8 The LRC data also show a substantial rise in triglyceride levels between the late teens and middle age for males. A steady rise also occurs in females, although the levels are consistently much higher in women taking sex hormones.
Males and Females
Our data permit comparisons of lipid distributions between males and females. Such comparisons should allow for the substantial impact of sex hormone usage on lipid distributions. Accordingly, in figure 7, data on females are confined to the group not taking sex hormones. These females have slightly higher median plasma cholesterol levels than males in the first 2 decades, lower levels until about age 50 years, and considerably higher levels thereafter. The median female triglyceride levels are slightly higher until about age 20 years; after that, the male levels are markedly higher 435 For the purpose of this presentation, the results of lipid distributions were aggregated across all participating clinics. The results are not those which would necessarily result from a random sample of the US population.
In fact, there is evidence of considerable interclinic variation, as shown by the highest and lowest clinicspecific median values shown in figures 1-6. The range of the cholesterol median values among the clinics is large and different for different age-race-sex groups; it reaches 18 mg/dl for white males ages 40-49 years and 24 mg/dl for females ages 50-59 years not taking hormones. The range of clinic-specific median values for triglycerides is even greater, being as much as 40 mg/dl for some of the subgroups.
The observed interclinic difference may be attributed in part to sampling variation. It could also be due to clinic differences in the distribution of lipidinfluencing factors such as genetic, dietary, behavioral, and comorbidity characteristics. The point to be emphasized is that the summary information, including means, medians and percentiles, does not represent fixed biologic attributes; rather, it is highly influenced by a large set of both known and unknown genetic and environmental factors. Therefore, the aggregated LRC lipid distributions presented here should not be used as fixed reference values, but as the combined results of contemporary surveys of a diverse set of populations. The lipid data are also presented as the baseline for descriptive and analytic epidemiologic LRC studies to be reported subsequently.
Cross-sectional Data These data are cross-sectional, and the cholesterol and triglyceride values are from samples of birth cohorts drawn from the several populations. Each of these defined populations is a biological unit, with definite limits to the variation that may occur in that population. Therefore, the relationships of lipid levels and age are likely to be a combination of actual changes with age, selective survival or participation, and cohort effects.
Response Rates
More than 60,000 subjects were examined at visit 1, with an overall response rate of 74%; however, there was substantial variation in response rates for each age, race, sex, and clinic subgroup. Although it compares favorably to several large-scale, populationbased studies, participation should be taken into account when considering the validity of the results. It is also pertinent that over 90% of all participants 437 screened had fasted for 12 hours or longer. This report includes data only for those fasting 12 hours or more.
Bias Considerations
A possible bias in these data is selective mortality, which is a potential flaw common to all cross-sectional surveys. (If plasma lipid levels are associated with increased mortality, spuriously lower population values of plasma lipids could be obtained in a crosssectional examination of survivors.) The magnitude of such bias, if present, cannot be readily ascertained.
A second source of potential bias is selective response, if factors associated with response are also determinants of lipid levels. Differential response rates by clinic are shown in table 1. Variations in response by age are discernible within clinics, with lower than average response rates in 20-25-year-olds and in those older than 75 years. In two clinics, response is also influenced by sex. Each of these characteristics is found to influence plasma lipid values in the LRC data and is controlled for in the analysis.
Some degree of bias cannot be ruled out if the response is less than complete, which is the characteristic common to population-based survey research. To estimate the magnitude of this potential bias is, however, speculative, since the attributes of the nonresponders are unmeasured. Short of recalling nonresponders, estimation of possible response bias remains inconclusive. While we cannot be certain the plasma lipid levels were the same in examined and nonexamined eligibles, there is no obvious reason to suspect differences in each age, sex and clinic group.
The Lipid Laboratories
Measurements of cholesterol and triglyceride levels were made by lipid laboratories located at each LRC. Further, five of the clinics, Baylor, Johns Hopkins, La Jolla, Seattle, and Stanford, which started a year earlier than the others, used the AutoAnalyzer I system. The other clinics used the AutoAnalyzer II system, since it was available by the time they started screening. The AA-LI system represented a considerable advance in the speed and ease of operation and in the precision of results. The first five clinics used the AA-I system throughout the study to maintain intraclinic comparability.
Plasma vs Serum
The LRC Prevalence Study evaluated plasma cholesterol and triglyceride, in contrast to most previous studies, which used serum. Plasma determinations were used at visit 1 
